Prihlásiť sa Zaregistrujte sa zadarmo

Návratnosť kapitálu spoločnosti Edesa Biotech

Aká je hodnota metriky Návratnosť kapitálu spoločnosti Edesa Biotech?

Hodnota metriky Návratnosť kapitálu spoločnosti Edesa Biotech, Inc. je -241.62%

Aká je definícia metriky Návratnosť kapitálu?



Return on capital employed (ROCE) je finančný ukazovateľ, ktorý meria rentabilitu spoločnosti a účinnosť spoločnosti vo využívaní vlastného kapitálu.

Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.

ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.

Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.

Návratnosť kapitálu spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Edesa Biotech

Čomu sa venuje spoločnosť Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Firmy s metrikou návratnosť kapitálu podobnou spoločnosti Edesa Biotech